These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 30006421)
1. Response to Checkpoint Inhibitor Therapy in Advanced Classic Kaposi Sarcoma: A Case Report and Immunogenomic Study. Saller J; Walko CM; Millis SZ; Henderson-Jackson E; Makanji R; Brohl AS J Natl Compr Canc Netw; 2018 Jul; 16(7):797-800. PubMed ID: 30006421 [TBL] [Abstract][Full Text] [Related]
2. Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade. Galanina N; Goodman AM; Cohen PR; Frampton GM; Kurzrock R Cancer Immunol Res; 2018 Oct; 6(10):1129-1135. PubMed ID: 30194084 [TBL] [Abstract][Full Text] [Related]
3. Frameshift events predict anti-PD-1/L1 response in head and neck cancer. Hanna GJ; Lizotte P; Cavanaugh M; Kuo FC; Shivdasani P; Frieden A; Chau NG; Schoenfeld JD; Lorch JH; Uppaluri R; MacConaill LE; Haddad RI JCI Insight; 2018 Feb; 3(4):. PubMed ID: 29467336 [TBL] [Abstract][Full Text] [Related]
4. The effects of human herpesvirus 8 infection and interferon-gamma response in cutaneous lesions of Kaposi sarcoma differ among human immunodeficiency virus-infected and uninfected individuals. Guedes F; de Andrade HF; Fernandes ER; Tuon FF; Brasil RA; Pagliari C; Duarte MI Br J Dermatol; 2008 Sep; 159(4):839-46. PubMed ID: 18644020 [TBL] [Abstract][Full Text] [Related]
5. Kaposi Sarcoma Updates. Etemad SA; Dewan AK Dermatol Clin; 2019 Oct; 37(4):505-517. PubMed ID: 31466590 [TBL] [Abstract][Full Text] [Related]
6. Reduced levels of neutralizing antibodies to Kaposi sarcoma-associated herpesvirus in persons with a history of Kaposi sarcoma. Kimball LE; Casper C; Koelle DM; Morrow R; Corey L; Vieira J J Infect Dis; 2004 Jun; 189(11):2016-22. PubMed ID: 15143468 [TBL] [Abstract][Full Text] [Related]
9. T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. Ott PA; Bang YJ; Piha-Paul SA; Razak ARA; Bennouna J; Soria JC; Rugo HS; Cohen RB; O'Neil BH; Mehnert JM; Lopez J; Doi T; van Brummelen EMJ; Cristescu R; Yang P; Emancipator K; Stein K; Ayers M; Joe AK; Lunceford JK J Clin Oncol; 2019 Feb; 37(4):318-327. PubMed ID: 30557521 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of plasma human herpesvirus 8 DNA as a marker of clinical outcomes during antiretroviral therapy for AIDS-related Kaposi sarcoma in Zimbabwe. Borok M; Fiorillo S; Gudza I; Putnam B; Ndemera B; White IE; Gwanzura L; Schooley RT; Campbell TB Clin Infect Dis; 2010 Aug; 51(3):342-9. PubMed ID: 20572760 [TBL] [Abstract][Full Text] [Related]
11. A case of classic Kaposi sarcoma in a 11-year-old male. Kalkan G; Akbay G; Gungor E; Eken A; Ozkaya O; Kutzner H; Eksioglu M Indian J Dermatol Venereol Leprol; 2011; 77(6):730. PubMed ID: 22016293 [No Abstract] [Full Text] [Related]
12. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041 [TBL] [Abstract][Full Text] [Related]
13. Molecular and Genomic Determinants of Response to Immune Checkpoint Inhibition in Cancer. Jenkins RW; Thummalapalli R; Carter J; Cañadas I; Barbie DA Annu Rev Med; 2018 Jan; 69():333-347. PubMed ID: 29099676 [TBL] [Abstract][Full Text] [Related]
14. Case of metastatic kaposi sarcoma successfully treated with anti-PD-1 immunotherapy. Cesmeci E; Guven DC; Aktas BY; Aksoy S J Oncol Pharm Pract; 2021 Oct; 27(7):1766-1769. PubMed ID: 33427037 [TBL] [Abstract][Full Text] [Related]
15. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells. Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928 [TBL] [Abstract][Full Text] [Related]
16. Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma. Bihl F; Mosam A; Henry LN; Chisholm JV; Dollard S; Gumbi P; Cassol E; Page T; Mueller N; Kiepiela P; Martin JN; Coovadia HM; Scadden DT; Brander C AIDS; 2007 Jun; 21(10):1245-52. PubMed ID: 17545700 [TBL] [Abstract][Full Text] [Related]
18. Low T cell responses to human herpesvirus 8 in patients with AIDS-related and classic Kaposi sarcoma. Guihot A; Dupin N; Marcelin AG; Gorin I; Bedin AS; Bossi P; Galicier L; Oksenhendler E; Autran B; Carcelain G J Infect Dis; 2006 Oct; 194(8):1078-88. PubMed ID: 16991082 [TBL] [Abstract][Full Text] [Related]
19. Human herpesvirus 8 in classic Kaposi sarcoma. Kemény L; Kiss M; Gyulai R; Kenderessy AS; Adám E; Nagy F; Dobozy A Acta Microbiol Immunol Hung; 1996; 43(4):391-5. PubMed ID: 9147730 [TBL] [Abstract][Full Text] [Related]
20. Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer. Mehrvarz Sarshekeh A; Overman MJ; Kopetz S Future Oncol; 2018 Aug; 14(18):1869-1874. PubMed ID: 29473436 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]